BioScrip Inc (NASDAQ:BIOS)’s share price traded down 5.1% on Monday . The stock traded as low as $2.86 and last traded at $2.95, 2,106,093 shares traded hands during trading. An increase of 89% from the average session volume of 1,111,532 shares. The stock had previously closed at $3.11.

Several analysts have weighed in on the company. Canaccord Genuity lifted their price objective on BioScrip from $3.50 to $4.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a report on Monday, November 11th. BidaskClub lowered shares of BioScrip from a “buy” rating to a “hold” rating in a report on Saturday, November 9th. SunTrust Banks lifted their target price on shares of BioScrip from $3.25 to $4.25 and gave the company a “buy” rating in a report on Friday, September 20th. Finally, Zacks Investment Research lowered shares of BioScrip from a “hold” rating to a “sell” rating and set a $4.00 target price for the company. in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $4.79.

The company has a market capitalization of $2.15 billion, a PE ratio of -6.02 and a beta of 0.44. The business’s fifty day moving average is $3.45 and its two-hundred day moving average is $2.95. The company has a current ratio of 1.71, a quick ratio of 1.36 and a debt-to-equity ratio of 1.43.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new position in BioScrip in the 2nd quarter worth approximately $27,000. Jane Street Group LLC purchased a new position in BioScrip in the 2nd quarter worth approximately $30,000. SG Americas Securities LLC purchased a new position in BioScrip in the 3rd quarter worth approximately $63,000. North Star Investment Management Corp. purchased a new position in BioScrip in the 3rd quarter worth approximately $64,000. Finally, JPMorgan Chase & Co. raised its holdings in BioScrip by 11.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 36,469 shares of the company’s stock worth $89,000 after acquiring an additional 3,683 shares during the last quarter. Institutional investors own 15.49% of the company’s stock.

About BioScrip (NASDAQ:BIOS)

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

See Also: Initial Coin Offering (ICO)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.